DFDenis Sergeevich Fedorinov

Denis Sergeevich Fedorinov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Denis Sergeevich Fedorinov has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Frequencies to Priorities: Interethnic Distribution of Pharmacogenetic Phenotypes as a Basis for Prioritizing Preemptive Testing in Russia’s Multiethnic Population

    by Karin B. Mirzaev, Sherzod P. Abdullaev, Svetlana N. Tuchkova, Firuz Kh. Turaev, Lyubov V. Selivanova, Denis S. Fedorinov, Dmitry A. Sychev

    Background/Objectives: The frequencies of pharmacogenetically relevant alleles and predicted phenotypes vary substantially between populations, with direct consequences for the expected efficacy and safety of widely prescribed drugs. Russia is one of the most ethnically diverse countries in the world, yet systematic, multi-gene pharmacogenetic data across its ethnic groups, and their implications for targeted implementation of testing, remain limited. This study aimed to characterize the distribution of predicted metabolizer phenotypes for CYP2C9, CYP2C19 and CYP3A5 and of predicted SLCO1B1 transporter function, together with VKORC1 and CYP4F2 genotypes, across 15 ethnic groups of Russia, and to establish the population-level frequency data required for subsequent analysis of regional priorities for pharmacogenetic testing. Methods: A total of 2304 unrelated individuals from 15 ethnic groups were genotyped for CYP2C9*2/*3, CYP2C19*2/*3/*17, CYP3A5*3, SLCO1B1*5, VKORC1 c.-1639G>A, CYP4F2*3, and ABCB1 c.3435C>T. Allele, genotype, and phenotype frequencies were estimated with 95% Wilson confidence intervals. Interethnic differences were assessed using the Fisher exact test (omnibus and pairwise comparisons against the Russian reference group), with the Benjamini–Hochberg false discovery rate correction; composite phenotype categories were further compared using 2 × 2 exact tests. Genotype-based expected warfarin maintenance dose ranges were assigned from CYP2C9 diplotype combined with VKORC1 genotype according to the FDA-approved prescribing information, with CYP4F2*3 carriage considered as a modifying factor. Results: Interethnic variability differed markedly by gene, ranging from minimal for CYP3A5 to pronounced for VKORC1. After correction for multiple comparisons, statistically significant differences from the Russian reference group were identified in up to eight of 14 ethnic groups per gene, affecting CYP2C9-, CYP2C19-, and SLCO1B1-related phenotypes relevant to NSAIDs, clopidogrel, proton pump inhibitors, antidepressants, and statins. The most pronounced pattern was a coordinated shift across CYP2C9 and CYP2C19 in Buryats and Nanais consistent with previously reported East Asian population patterns, alongside an isolated, population-specific extreme in Lezgins, who showed the highest CYP2C9 intermediate/poor metabolizer frequency of all 15 groups. These differences translated into markedly divergent distributions of genotype-based expected warfarin dose ranges, with the lowest range (0.5–2 mg/day) expected in 21.1% of Lezgins, compared with 8.8% overall, and the 3–4 mg/day range predominating in Buryats and Nanais (69.3% and 73.9%). Conclusions: These findings characterize the pharmacogenetic landscape of Russia’s understudied ethnic diversity and provide the population-level frequency data required as one component of any subsequent assessment of where preemptive pharmacogenetic testing should be prioritized–an assessment that additionally requires data on prescribing patterns, clinical outcomes, cost-effectiveness and healthcare infrastructure. The magnitude of the interethnic differences documented here nonetheless indicates that implementation planning guided by population-specific rather than nationally averaged frequencies merits further evaluation in a multiethnic country.

  • Open Access

    Impact of Cytochrome P450 and P-glycoprotein Gene Polymorphisms on the Risk of Hemorrhagic Complications in Older Patients with Non-Valvular Atrial Fibrillation Treated with Rivaroxaban

    by Ivan V. Sychev, Andrey P. Kondrakhin, Sherzod P. Abdullaev, Pavel O. Bochkov, Svetlana N. Tuchkova, Lyubov V. Selivanova, Denis S. Fedorinov, Olga A. Milovanova, Karin B. Mirzaev, Dmitry A. Sychev

    Background: The administration of direct oral anticoagulants to older adults requires careful risk stratification against a backdrop of polypharmacy and age-related renal function decline. The role of single nucleotide polymorphisms in cytochrome P450 genes and efflux transporters in this context remains a clinically understudied issue. This study aimed to investigate the association of ABCB1, CYP3A4, and CYP3A5 allelic variants with the safety of rivaroxaban therapy in geriatric patients with non-valvular atrial fibrillation (AF). Materials and Methods: This prospective cohort study consecutively enrolled 94 patients (mean age 83.2 ± 9.2 years). Rivaroxaban trough plasma concentrations (Cmin,ss ) were quantified using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay. Real-time polymerase chain reaction was utilized for the molecular genetic profiling of the ABCB1 (rs1045642, rs2032582), CYP3A4*22 (rs35599367), and CYP3A5*3 (rs776746) loci. Comorbidity severity and the spectrum of drug–drug interactions were evaluated as additional predictors. Results: Clinically relevant hemorrhagic complications were documented in 36.2% (n = 34) of the monitored patients. A significant association was established between the homozygous CC genotype at the ABCB1 rs1045642 locus and increased bleeding propensity (odds ratio [OR] 2.42; 95% CI: 1.02–5.74; p = 0.042), whereas the alternative TT variant was associated with a pronounced protective effect. No statistically significant correlations were identified for biotransformation isoenzyme markers (CYP3A4*22, CYP3A5*3). Anticoagulant metrics were comparably distributed across groups and showed no dependence on genetic status. The leading non-genetic factors associated with hemorrhage were advanced age (p < 0.0001), progressive glomerular filtration rate decline (CKD stages 3b–4; p = 0.0009), and pharmacokinetic/pharmacodynamic interference from the co-administration of amiodarone (OR 3.61), non-steroidal anti-inflammatory drugs, and antiplatelet agents. The validated HAS-BLED score demonstrated no predictive power within the comorbid conditions of this cohort (p = 0.052). Conclusions: The ABCB1 rs1045642 (C3435T) polymorphism is associated with the occurrence of hemorrhagic events. Implementing pharmacogenetic testing of the P-glycoprotein transporter combined with a rigorous audit of renal excretory function and concomitant therapy management may optimize the safety profile of rivaroxaban in geriatric practice. These findings warrant confirmation in a larger cohort.

  • Open Access

    Allelic Variants of the DPYD Gene in Russian Patients with Cancer: The Results of Exome Sequencing

    by Denis Fedorinov, Vladimir Lyadov, Marina Lyadova, Sherzod Abdullaev, Ivan Sychev, Anna Filatova, Lavrentii Danilov, Oleg Glotov, Iuliia Budagova, Karin Mirzaev, et al.

    Background/Objectives: Pharmacogenetic testing of the dihydropyrimidine dehydrogenase gene (DPYD) is increasingly incorporated into clinical practice to identify patients at increased risk of fluoropyrimidine-related toxicity. However, most routine assays target a limited number of well-established variants, whereas the DPYD gene demonstrates substantial population variability and may harbor rare potentially functional alleles that are not detected by conventional targeted testing. Data describing coding and splice-region DPYD variants detectable by whole-exome sequencing in Russian oncology populations remain limited. This study aimed to characterize the frequency and distribution of common, clinically relevant, and rare DPYD variants in a Russian cohort of patients receiving fluoropyrimidine-containing chemotherapy and to compare the observed allele frequencies with European and East Asian reference populations. Methods: Descriptive pharmacogenetic analysis was performed in 339 patients with malignant tumors treated with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT), folinic acid, fluorouracil, and oxaliplatin (FOLFOX), or folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) regimens. Whole-exome sequencing was performed using Illumina technology with exome enrichment by KAPA HyperExome and a sequencing depth of at least 100×. Sequence reads were aligned to the Genome Reference Consortium Human Build 38 (GRCh38) reference genome, germline variants were called using Genome Analysis Toolkit (GATK), HaplotypeCaller, and functional annotation was performed with Ensembl Variant Effect Predictor. DPYD variants were classified according to their population frequency, predicted functional effect, ClinVar annotations, and current pharmacogenetic recommendations. Allele and genotype frequencies were calculated and descriptively compared with Genome Aggregation Database (gnomAD) v4.1.1 Non-Finnish European and East Asian populations. Results: Seventeen DPYD variants were identified. The most frequent alternative alleles were rs1801265 (24.93%), rs1801159 (17.70%), rs2297595 (11.06%), rs1801160 (7.08%), and rs17376848 (5.16%). Their distribution was generally closer to that observed in the Non-Finnish European population than in East Asian populations. The established reduced-function variant rs67376798 (c.2846A>T, p.Asp949Val) was detected in one heterozygous patient, corresponding to a carrier frequency of 0.29% and an allele frequency of 0.15%. The HapB3 proxy variant rs56038477 (c.1236G>A) was identified in 13 heterozygous patients, with a carrier frequency of 3.83% and an allele frequency of 1.92%; confirmation of the functional intronic variant rs75017182 would be required for definitive HapB3 assignment. Overall, rs67376798 or rs56038477 was detected in 14 patients (4.13%). In addition, rare variants with a cohort allele frequency below 1% were identified in 11 patients (3.24%). Among these, p.Thr65Ala, p.Thr65Met, p.Asn151Asp, and p.Val691Leu represented potentially relevant findings requiring further functional validation. Conclusions: Whole-exome analysis revealed a heterogeneous spectrum of DPYD variants in the studied Russian oncology cohort, including both established pharmacogenetic markers and rare variants that would not be captured by limited targeted panels. The overall allele-frequency pattern was predominantly similar to that of European reference populations, although several rare variants demonstrated distinct distributions. These findings support the value of population-specific characterization of DPYD and suggest that expanded sequencing approaches may complement conventional pharmacogenetic testing by identifying rare potentially functional alleles.

  • Prophylactic embolization of the left gastric artery before neoadjuvant chemotherapy in gastric cancer patients

    by V.K. Lyadov, A.I. Zagorulko, T.S. Boldyreva, D.A. Skhalyakhov, D.S. Fedorinov

    Transarterial embolization (TAE) is an effective method of hemostasis, but the prophylactic use of this procedure in patients with a high risk of bleeding remains poorly studied. Objective. To evaluate the clinical efficacy and safety of the left gastric artery TAE in patients with resectable gastric cancer and a history of gastrointestinal bleeding before neoadjuvant polychemotherapy (NAPCT). Material and methods. A single-center retrospective non-randomized study was conducted. Treatment results were analyzed in 14 patients (mean age 65±9 years) with resectable gastric cancer and a history of tumor bleeding, who underwent prophylactic embolization of the left gastric artery using microcoils or microspheres before NAPCT at the S.S. Yudin City Clinical Hospital from 2022 to 2024. The technical success of the procedure, the presence of bleeding recurrence and the tumor regression grade (TRG) were assessed. Results. TAE was technically successful in 12 patients (85.7%), of which 10 patients did not experience bleeding recurrence during NAPCT. Radical surgery was possible after successful TAE and NAPCT in 8 patients. There were 4 mild complications: post-embolization syndrome — 3, hematoma — 1. TRG according to Mandard classification constituted 1 — 1 case, 3 — 5 cases, 4 — 2 patients. Conclusion. Prophylactic embolization of the left gastric artery before NAPCT in patients with gastric cancer and tumor bleeding history is a clinically effective and safe procedure that can reduce the risk of bleeding recurrence and improve the tolerability of chemotherapy. However, further studies are needed to clarify the indications and evaluate the long-term results.

  • Open Access

    Impact of Pharmacogenetic Markers on the Efficacy of Neoadjuvant FLOT Chemotherapy in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma

    by Denis Fedorinov, Vladimir Lyadov, Marina Lyadova, Sherzod Abdullaev, Anastasia Kachanova, Anna Filatova, Dmitriy Ivashchenko, Dmitry Sychev

    Despite the adoption of neoadjuvant FLOT chemotherapy as standard treatment for locally advanced gastric and gastroesophageal junction cancer, many patients fail to achieve meaningful pathological response, limiting efficacy. The aim of this study was to evaluate the impact of pharmacogenetic markers on pathological response in Russian patients receiving neoadjuvant FLOT. Thirty patients with locally advanced gastric or gastroesophageal junction adenocarcinoma received neoadjuvant FLOT followed by surgery. Polymorphisms in CYP3A5 (rs776746), CYP2C8 (rs10509681, rs11572080, rs1058930), ERCC1 (rs11615), and GSTP1 (rs1695) were analyzed. Favorable pathological response (TRG0-2) was observed in 23.3% of patients, including 3.3% complete responses. Most patients (76.7%) had minimal or no regression (TRG3-5). Clinical variables were not associated with response. ERCC1 (rs11615) showed a significant association: patients with the Wt/Wt genotype had higher odds of achieving TRG0-2 (OR = 8.889; p = 0.033; 95% CI: 1.294–61.058). No associations were found for CYP3A5, CYP2C8, or GSTP1. Median PFS was 18.21 months in TRG3-5, while not reached in TRG0-2 (p = 0.108). No significant PFS differences by ERCC1 genotype were observed (p = 0.525). ERCC1 (rs11615) may serve as a potential pharmacogenetic marker of response to FLOT, supporting further research in personalized treatment strategies.

  • Open Access

    Comparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice

    by Evgeniya S. Kuzmina, Mikhail I. Fedyanin, Polina S. Feoktistova, Marina A. Lyadova, Denis S. Fedorinov, Olga R. Magamedova, Sergey A. Parts, Maxim A. Polyanskiy, Egor P. Fekhtel, Ilya A. Pokataev, et al.

    Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.

  • Open Access

    Efficacy of immunotherapy in patients with locally advanced colorectal cancer and microsatellite instability: a case series

    by Oleg N. Zauzolkov, Marina A. Lyadova, Vladimir K. Lyadov, Denis S. Fedorinov, Evgeniya A. Kulikova, Dmitrii V. Erygin, Evgenii V. Ledin, Julia S. Mansurova

    AIM : to assess the efficacy of immunotherapy in patients with locally advanced CRC and MSI. PATIENTS AND METHODS: three clinical cases of patients with locally advanced colorectal cancer and microsatellite instability are presented. RESULTS: all three patients experienced major clinical and radiological improvement shortly after the start of ICI treatment. The third patient developed a 2nd degree immune-mediated pneumonitis that necessitated hormonal therapy and ICI termination. This patient got a subsequent laparoscopic right colectomy which proved complete pathomorphologic response. Recurrent-free survival since the beginning of ICI treatment is 54, 30 and 18 months, respectively. CONCLUSION: patients with locally advanced CRC and MSI even in case of unresectability may benefit greatly after immunotherapy. This makes it crucial to evaluate the presence of MSI in this patients.


  • Open Access

    Development of diabetes mellitus on the background of immunotherapy in patients with malignant neoplasms: A retrospective study

    by Marina A. Lyadova, Olesya A. Pardabekova, Denis S. Fedorinov, Tatiana G. Antonova, Elina A. Khachaturian, Maxim M. Sobolev

    Background. Endocrinopathies are a subset of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICTI) immunotherapy, of which diabetes mellitus (irDM) is one of the most serious. Aim. To describe peculiarities of DM development against the background of immunotherapy in patients with malignant neoplasms on the example of a series of clinical cases. Materials and methods. Seven patients with melanoma, non-small-cell lung cancer and renal cancer aged 43 to 69 years, who developed DM against the background of immunotherapy (nivolumab, ipilimumab, pembrolizumab, atezolizumab both as monotherapy and combined treatment) were included in the retrospective study. Results. Partial response was observed in 1 patient, stabilization – in 6 patients. The median of time before the development of DM was 10.13 months. Complications of DM were observed in 4 patients, and other irAEs developed in 5 patients. Fatal outcome was observed in 2 patients, due to progression of the underlying disease (1 patient) and development of coma due to insulin-dependent DM (1 patient). Conclusion. IrDM is a rare but extremely serious complication of ICTI therapy that requires clear definition of diagnostic criteria. Identification of premorbid predictors of irDM may allow for targeted treatment trials and earlier detection of this complication of ICTI therapy.

  • Open Access

    Evaluation of drug-drug interactions in patients receiving FOLFOX chemotherapy: A prospective study

    by Denis S. Fedorinov, Marina A. Lyadova, Vladimir K. Lyadov, Dmitry A. Sychev

    Aim. To evaluate the frequency and clinical significance of drug-drug interactions (DDI) in patients receiving drug antitumor therapy using the Drugs® and Medscape® DDI calculators. Materials and methods. The study included 282 patients with a mean age of 65 years (36–84) who received FOLFOX chemotherapy, of whom 151 (53%) were males and 131 (47%) were females. At the start of the first course of chemotherapy, 214 (75%) patients were receiving concomitant therapy on a regular basis. Results. The odds of severe toxicity in patients receiving concomitant therapy were 2.720 times higher [95% confidence interval (CI) 1.025–7.218; p=0.038]. Patients with strong DDI were statistically significantly more likely to develop mucositis after the first course of drug antitumor therapy: 14 (38.9%) vs 36 (20.2%) according to Drugs®, p=0.041; 22 (33.3%) vs 28 (18.9%) according to Medscape®; p=0.036. Similar results were obtained in a subgroup of patients at risk of QT prolongation according to Drugs® – 10 (52.6%) vs 40 (20.5%); p0.001. Patients taking calcium channel blockers were statistically significantly more likely to develop dose-limiting toxicity: 18 (40.9%) vs 52 (21.8%). The odds of dose-limiting toxicity were 2.476 times higher: 95% CI 1.261–4.864; p=0.007. Conclusion. The incidence of DDI in patients with gastrointestinal tumors receiving FOLFOX best supportive therapy can be as high as 90.2%, with one in three DDI classified as serious. Drugs® and Medscape® DDI services cover only 80% of concomitant medications and are not adapted to oncology, necessitating the development of more versatile approaches.

  • Open Access

    Towards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort

    by Denis Fedorinov, Vladimir Lyadov, Marina Lyadova, Sherzod Abdullaev, Anastasia Kachanova, Rustam Heydarov, Igor Shashkov, Sergey Surzhikov, Vladimir Mikhailovich, Dmitry Sychev

    Background/Objectives: Pharmacogenetic variability plays a crucial role in determining both the efficacy and toxicity of chemotherapy for gastrointestinal cancers. However, data on allele frequencies and their clinical relevance in Russian populations remain scarce. Methods: We conducted a prospective observational study of 412 patients with gastrointestinal malignancies between 2020 and 2023. Pharmacogenetic testing was performed prior to the initiation of chemotherapy using real-time allele-specific PCR and microarray hybridization technology. Polymorphisms in the DPYD, UGT1A1, CYP2C8, CYP3A5, GSTP1, ERCC1, XPC, CDA, MTHFR, TYMS, and SLC31A1 genes were analyzed. Results: The frequency of most variants was consistent with those reported in European populations, reflecting the ethnic proximity of the studied cohort. Several clinically relevant variants were identified: DPYD rs2297595 occurred more frequently than in European cohorts, and UGT1A1 rs8175347 was observed at a higher prevalence, underscoring the potential risk of irinotecan-related neutropenia and diarrhea. CYP2C8 rs10509681 was present at frequencies comparable to European populations and is associated with an increased risk of taxane-induced peripheral neuropathy. Other markers (GSTP1, ERCC1, CDA, SLC31A1, MTHFR, TYMS) demonstrated variable associations with chemotherapy efficacy and toxicity, consistent with findings from previous international studies. Conclusions: This study provides the first comprehensive description of pharmacogenetic polymorphisms in a Russian cohort of patients with gastrointestinal cancers. Our findings confirm the clinical importance of DPYD and UGT1A1 testing and highlight additional variants of potential interest.